CDX-0159 for Chronic Urticaria

"This clinical trial has an age eligibility of 18 years or older and 75 years old or younger."

"The clinical trial hosted on clinicaltrials.gov is no longer recruiting participants, as the last edit to its page was made on August 31st 2022. Despite this being the case, there are still 36 other studies actively searching for patients at this current time."

"This trial requires 40 participants aged between 18 and 75 who are currently suffering from urticaria. To qualify for the study, patients must have been using H1-antihistamines alone or in combination with H2-antihistamines and/or leukotriene receptor antagonists over the past 3 days; possess no other medical issues which would cause further risk or hinder procedures; display itchiness and hives consistently for at least 6 weeks prior to Visit 1 despite current use of drugs; desire to finish a daily symptom electronic diary throughout the duration of treatment and be able to keep up with visit times; demonstrate an UAS"

"At present, the enrolment process is occurring in 12 sites across America. These include Birmingham, Indianapolis and Tampa as well as other cities. To lessen travel needs if you choose to partake, pick a site that's nearest to your residence."

"Due to the limited data surrounding CDX-0159, our team at Power has assigned it a safety score of 1. This rating is because this trial only in its first phase and there's an absence of sufficient evidence demonstrating efficacy or security."